Drug resistance in ovarian cancer and potential for its reversal
Ovarian cancer is characterized as a disease responsive to chemotherapy and current medical treatment strategies are based on the use of a platinum containing anticancer drug, either cisplatin or carboplatin, as the cornerstone of post surgical treatment [1,2]. Unfortunately, the majority of patients with stage III or IV disease are not cured by platinum containing combination chemotherapy and when ovarian cancers recur, especially after short disease-free intervals, they are generally refractory to a variety of other unrelated chemotherapeutic agents [1,3]. It is clear that our understanding of this aspect of ovarian cancer biology could have substantial clinical impact if approaches to reverse the failure of therapy or prevent treatment failure could be discovered.
KeywordsOvarian Cancer Cell Line Gynecologic Oncology Group Human Ovarian Cancer Cell Line Buthionine Sulfoximine Develop Cell Line
Unable to display preview. Download preview PDF.
- 1.Ozols, R.F., O’Dwyer, P.J. and Hamilton, T.C. (1993) Drug resistance in ovarian cancer. In Cancer of the Ovary (eds M. Markman and W. Hoskins), W.B. Saunders, Philadelphia, pp. 261–76.Google Scholar
- 14.Van Houten, B. (1990) Nucleotide excision repair in Escherichia coli. Microbiol Rev. 54, 18–51.Google Scholar
- 17.O’Dwyer, P.J., Moyer, J.D., Suffness, M. et al (1994) Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res. 54, 724–9.Google Scholar
- 20.Hosking, L.K., Whelan, R.D.H., Shellard, S.A. e t al (1990) An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumor cell lines. Biochem. Pharmacol 40,1833–42.Google Scholar
- 23.Hamilton, T.C., Winker, M.A., Louie, K.G. et al (1985) Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug- resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol 34, 2583–6.PubMedCrossRefGoogle Scholar
- 27.Bookman, M. A, Caron, D. A., Hogan, W. M. et al (1993) Phase-1 evaluation of dose-intense chemotherapy with interleukin-1α: (ILl-α) for gynecologic mahgnancies. Proc. ASCO 12, A868.Google Scholar
- 28.Calvert, A.H., Newell, D.R., Gumbrell, L.A. et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol 11748–56.Google Scholar
- 29.McGuire, W.P., Hoskins, W.J., Brady, M.F. et al (1993) A Phase III trial comparing cisplatin/Cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC). Proc. ASCO 12, A808.Google Scholar
- 30.Ozols, R. F., Kilpatrick, D., O’Dwyer, P. et al (1993) Phase I and pharmacokinetic study of taxol (T) and carboplatin (C) in previously untreated patients (PTS) with advanced epithelial ovarian cancer (OC): a pilot study of the Gynecologic Oncology Group.Proc. ASCO 12, A824.Google Scholar